{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=immunologic+technique&page=16", "query": { "intervention": "immunologic technique", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 583, "total_pages": 59, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=immunologic+technique&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=immunologic+technique&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T22:25:04.568Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01382706", "title": "Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Bladder Cancer", "Stage III Bladder Cancer", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2011-06-13", "completion_date": "2017-12-15", "has_results": true, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01382706" }, { "nct_id": "NCT00361049", "title": "Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "graft versus host disease prophylaxis/therapy", "type": "BIOLOGICAL" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2004-09", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2010-11-05", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 8, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00361049" }, { "nct_id": "NCT00909831", "title": "Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "hydroxychloroquine", "type": "DRUG" }, { "name": "temsirolimus", "type": "DRUG" }, { "name": "electron microscopy", "type": "OTHER" }, { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "autophagy inhibition therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 40, "start_date": "2008-10", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00909831" }, { "nct_id": "NCT02596724", "title": "TME Neoadjuvant Breast Registry", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Breast Neoplasms" ], "interventions": [ { "name": "Genomic and/or molecular testing of blood or tissue", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Targeted Medical Education", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 1000, "start_date": "2015-07", "completion_date": "2022-07", "has_results": false, "last_update_posted_date": "2015-11-05", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 4, "location_summary": "Los Gatos, California • Allentown, Pennsylvania • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Gatos", "state": "California" }, { "city": "Allentown", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02596724" }, { "nct_id": "NCT00863668", "title": "Raltegravir Activity In Lymphoid Tissues", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infection", "HIV Infections" ], "interventions": [ { "name": "Efavirenz + Tenofovir DF/Emtricitabine", "type": "DRUG" }, { "name": "Raltegravir + Tenofovir DF/Emtricitabine", "type": "DRUG" }, { "name": "Colonoscopy with biopsies", "type": "PROCEDURE" }, { "name": "Inguinal Lymph Node Excision", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-03", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2015-05-18", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00863668" }, { "nct_id": "NCT01656135", "title": "Reference Group Trial for The ONE Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End-stage Renal Failure", "Kidney Graft Rejection" ], "interventions": [ { "name": "Blood drawing for immune monitoring and questionnaires", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Regensburg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2012-12", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-03-09", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 2, "location_summary": "San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656135" }, { "nct_id": "NCT01414426", "title": "Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lip and Oral Cavity Squamous Cell Carcinoma", "Oral Cavity Verrucous Carcinoma", "Precancerous Condition" ], "interventions": [ { "name": "vandetanib", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2012-01", "completion_date": "2019-06-01", "has_results": true, "last_update_posted_date": "2021-01-14", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414426" }, { "nct_id": "NCT01020097", "title": "Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Squamous Cell Carcinoma" ], "interventions": [ { "name": "fluorine F18 EF5", "type": "DRUG" }, { "name": "immunohistochemistry staining method", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "Positron Emission tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2009-03", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2020-04-28", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01020097" }, { "nct_id": "NCT00228358", "title": "Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "Recurrent Breast Cancer", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Stage IV Breast Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor" ], "interventions": [ { "name": "ex vivo-expanded HER2-specific T cells", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "denileukin diftitox", "type": "BIOLOGICAL" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2003-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-11-11", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00228358" }, { "nct_id": "NCT00453050", "title": "Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)", "Metastatic Cancer" ], "interventions": [ { "name": "imiquimod", "type": "DRUG" }, { "name": "indocyanine green solution", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-06", "last_synced_at": "2026-10-19T22:25:04.568Z", "location_count": 1, "location_summary": "Tulsa, Oklahoma", "locations": [ { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00453050" } ] }